Diabetes
is one of the largest therapeutic segments of global
pharmaceutical sales and during the last 10 years
it has grown by a compound average growth rate of
nearly 20% from around US$4 billion in 1995 to over
US$17 billion in 2005. Overall, anti-diabetic drugs
sales are expected to grow dramatically over the
next five years to over US$22 billion in 2012 as
the addressable patient population continues to
increase and new, oral, injectable and pulmonary
premium priced products enter the market to address
high unmet clinical needs.
The
Global Diabetes Market assesses the markets for
diabetes therapeutics, as well as the markets for
diagnostic products and those that treat diabetic
complications. This report from Arrowhead Publishers
incorporates new clinical findings presented at
the 2006 conference of the American Diabetes Association
into our product outlooks and financial forecasts.
This report also analyzes, clinically and financially,
the leading products on the market, the major players,
as well as the groundbreaking new products in clinical
development. Financial forecasts are also provided
for individual products as well as for product classes.
Key Features of This Report:
-
A thorough global market breakdown of key products
and players in the non-insulin, insulin, diagnostic
and diabetic neuropathy areas
-
Individual
chapters outlining the drivers of and resistors
on this growing market
-
Clinical evaluations of products and product classes
in both the insulin and non-insulin markets
-
Financial
forecasts through 2012 for products and product
classes in the areas of insulin, non-insulin,
alternative therapies and diabetic complications
-
Thorough
analysis of products in clinical development,
including coverage of safety, efficacy, market
potential and filing timelines
-
96
tables/figures illustrating scientific and market
aspects of the global diabetes market
|
